GE’s ASIR cuts CT dose
A type of iterative reconstruction may reduce patient radiation dose from CT scans up to 65%, according to a study published in the September issue of the American Journal of Roentgenology.
GE’s ASIR cuts CT dose
A type of iterative reconstruction may reduce patient radiation dose from CT scans up to 65%, according to a study published in the September issue of the American Journal of Roentgenology. The technique, called adaptive statistical iterative reconstruction (ASIR) by its developer, GE Healthcare, reduces noise in the image, allowing a downward adjustment in radiation dose to obtain standard diagnostic quality images. Researchers at the Mayo Clinic Arizona in Scottsdale found nearly identical image quality using the reduced dose CT method with ASIR compared with the standard dose CT method without ASIR in CT scans on a phantom and 12 patients. Patient radiation doses were reduced up to 65% using the low-dose IR method, they said. The average dose delivered during the low-dose CT with IR was 470 mGy; the average dose delivered using the standard dose CT without IR was 894 mGy.
Could AI-Powered Abbreviated MRI Reinvent Detection for Structural Abnormalities of the Knee?
April 24th 2025Employing deep learning image reconstruction, parallel imaging and multi-slice acceleration in a sub-five-minute 3T knee MRI, researchers noted 100 percent sensitivity and 99 percent specificity for anterior cruciate ligament (ACL) tears.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
